• Latest Posts

After only 6 months, Akarna seals the deal with Allergan for €44.8M upfront

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Here’s why this leading EU Investor turned to NASH

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition


Phenex sells out its main programme to Gilead